We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

16 hedge funds and large institutions have $2.78M invested in Sonoma Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.01% less ownership

Funds ownership: 0.07% → 0.05% (-0.01%)

16% less funds holding

Funds holding: 19 → 16 (-3)

23% less capital invested

Capital invested by funds: $3.62M → $2.78M (-$839K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$19.7K
2
Deutsche Bank
Deutsche Bank
Germany
+$9.87K
3
Morgan Stanley
Morgan Stanley
New York
+$4.93K
4
BlackRock
BlackRock
New York
+$3.7K
5
UBS Group
UBS Group
Switzerland
+$3.7K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$143K
2
VKH
Virtu KCG Holdings
New York
-$94K
3
RJA
Raymond James & Associates
Florida
-$81K
4
Renaissance Technologies
Renaissance Technologies
New York
-$37K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$12.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
1
Bard Associates
Illinois
$814K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$684K -$143K -116 -17%
JAM
3
JW Asset Management
Florida
$668K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$260K -$37K -30 -12%
BlackRock
5
BlackRock
New York
$186K +$3.7K +3 +2%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$87K -$12.3K -10 -12%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$20K +$19.7K +16 +1,600%
Morgan Stanley
8
Morgan Stanley
New York
$17K +$4.93K +4 +36%
UBS Group
9
UBS Group
Switzerland
$12K +$3.7K +3 +50%
Deutsche Bank
10
Deutsche Bank
Germany
$9K +$9.87K +8 New
Bank of America
11
Bank of America
North Carolina
$7K -$2.47K -2 -29%
Wells Fargo
12
Wells Fargo
California
$7K – – –
HFM
13
Hartford Financial Management
Connecticut
$5K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$4K – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$2K +$2.47K +2 New
LTFS
16
Ladenburg Thalmann Financial Services
Florida
$1K – – –
VKH
17
Virtu KCG Holdings
New York
– -$94K -73 Closed
RJA
18
Raymond James & Associates
Florida
– -$81K -62 Closed
AIM
19
Acrospire Investment Management
Illinois
– -$2K -1 Closed
Creative Planning
20
Creative Planning
Kansas
– -$2K -1 Closed

SNOA Hedge Fund Activity: Q2 2017 in Review

16 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2017, worth a combined $2.78M — down 23% from $3.62M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SNOA and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Acadian Asset Management, adding an estimated $19.7K. The largest seller was Vanguard Group, cutting an estimated $143K.

  • 16 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2017, down from 19 in Q1 2017.
  • Funds reported $2.78M of Sonoma Pharmaceuticals stock for Q2 2017, down 23% quarter-over-quarter.
  • 2 funds opened new Sonoma Pharmaceuticals positions in Q2 2017 and 4 closed out, a net change of -2 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q2 2017 was Acadian Asset Management, an estimated $19.7K added.
  • The largest Sonoma Pharmaceuticals seller in Q2 2017 was Vanguard Group, an estimated $143K sold.

Based on aggregated 13F filings for Q2 2017.